AstraZeneca Volrustomig Trial Halted Amid Growing Pipeline Concerns

AstraZeneca has suffered another setback in its development pipeline after halting a late-stage trial for its experimental drug volrustomig, which was being tested to treat a certain type of lung cancer.

The decision comes on the heels of a series of blows that have dented investor confidence in the British drugmaker. In addition to the discontinuation of this trial, AstraZeneca has also faced setbacks with its Wainua heart disease trial and its breast cancer drug camizestrant.

According to the company, an independent data monitoring committee recommended halting the volrustomig trial due to concerns that it was unlikely to help patients live longer or keep their disease from worsening compared to Merck's blockbuster immunotherapy Keytruda plus chemotherapy.

However, AstraZeneca reported positive readouts from two other late-stage lung cancer trials, which helped lift its shares by nearly 1%. The company had previously predicted over $5 billion in peak sales from volrustomig, but the discontinuation of this trial is unlikely to impact its ambitious goal of reaching $80 billion in annual revenue by 2030.

AstraZeneca's executive vice president for oncology haematology R&D, Susan Galbraith, said that the company will learn from this trial and continue to move forward with other development projects. The company is counting on up to 20 new drug launches to help reach its revenue target.